| |
Presentation |
Media |
Date |
|
Watch the interview at Redeye with CEO Martin Jönsson and Märta Segerdahl MD, PhD. Last patient included in AlzeCure’s Phase II clinical trial in peripheral neuropathic pain with the non-opioid ACD440. (Swedish)
|
|
|
January 31, 2023
|
|
CEO Martin Jönsson’s interview with Redeye, the outcome of the issue and milestones in 2023, 9 January (Swedish)
|
|
|
January 9, 2023
|
|
Erik Penser – Interview with CSO Johan Sandin about AlzeCure’s projects.
|
|
|
December 13, 2022
|
|
Interview at Finwire news with CEO Martin Jönsson (The presentation will be held in Swedish).
|
|
|
December 12, 2022
|
|
Rights Issue presentation with CEO Martin Jönsson at Erik Penser Bank.
|
|
|
December 6, 2022
|
|
Erik Penser – Interview with Martin Jönsson about the ongoing Rights Issue.
|
|
|
December 6, 2022
|
|
CEO Martin Jönsson presents AlzeCure at BioStock.
|
|
|
December 5, 2022
|
|
AlzeCure’s CEO Martin Jönsson presents at BioStock in connection with a new share issue, December 5, 2022.
|
|
|
December 5, 2022
|
|
AC-0027875, a novel gamma-secretase modulator. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.
|
|
|
November 30, 2022
|
|
Preclinical characterization of ACD856. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.
|
|
|
November 30, 2022
|
|
Quantitative EEG results from a multiple ascending dose study. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.
|
|
|
November 30, 2022
|
|
CEO Martin Jönsson interviewed at Redeye Life Sciences Day on the company’s positive development & plans, as well as about the proposed rights issue in December and the positive progress in the Alzheimer’s market, and what this means for AlzeCure.
|
|
|
November 24, 2022
|
|
Martin Jönsson presented at Life Science Investor Conference the company’s successes and ongoing projects, as well as the company’s new share issue.
|
|
|
November 23, 2022
|
|
CEO Martin Jönsson presents AlzeCure’s progress and ongoing projects, as well as the company’s proposed share issue. (English)
|
|
|
November 17, 2022
|
|
Aktiespararna’s event with AlzeCure on November 16, 2022 – Martin Jönsson, AlzeCure’s CEO, presented the company’s progress and ongoing projects, as well as the company’s planned share issue. The presentation was held in Swedish.
|
|
|
November 16, 2022
|
|
CEO Martin Jönsson presented the company’s latest developments at Redeye Theme: Neurology on October 12, 2022.
|
|
|
October 12, 2022
|
|
CEO Martin Jönsson presented an update on our Pain management projects at Redeye Theme: Neurology on October 12.
|
|
|
October 12, 2022
|
|
The Trk-PAM ACD856 improves mitochondrial function and increases BDNF levels in primary cortical neurons; Scientific presentation at the ISMND Conference, Athens, October 10-12, 2022.
|
|
|
October 11, 2022
|
|
Analgesic and Anti-inflammatory Effects of Small Molecule Negative Allosteric Modulators of TrkA; Scientific presentation at the IASP Conference, Toronto, September 19-23, 2022.
|
|
|
September 22, 2022
|
|
Martin talks about the latest developments for AlzeCure including the phase 2 study with ACD 440 against neuropathic pain, the new positive clinical results with NeuroRestore ACD 856, our new patent and the new results with the pain project TrkA-NAM. (Swedish).
|
|
|
September 12, 2022
|
|
Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the latest clinical progress (Swedish).
|
|
|
September 1, 2022
|
|
Results From a Multiple Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors AAIC July – Aug 2022.
|
|
|
July 31, 2022
|
|
Watch the interview with Aktiespararna at Finwire with AlzeCure’s CEO Martin Jönsson. (Swedish).
|
|
|
July 1, 2022
|
|
AlzeCure – Interview at Redeye with CEO Martin Jönsson about the phase II study with ACD440. (Swedish).
|
|
|
June 23, 2022
|
|
AlzeCure at Redeye Growth Day.
|
|
|
June 2, 2022
|
|
CEO Martin Jönsson Presenting at Redeye Growth Day.
|
|
|
May 23, 2022
|
|
The use of PathHunter cell lines to discover modulators of Trk-receptors. From HTS to phase 1; Scientific presentation at the ELRIG Conference, Gothenburg, May 10-12, 2022.
|
|
|
May 10, 2022
|
|
AlzeCure – Alzheimer event at Redeye (Swedish).
|
|
|
3 May, 2022
|
|
Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm.
|
|
|
April 21, 2022
|
|
Preliminary Results From a Single Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm,
|
|
|
April 21, 2022
|
|
Identification of a positive modulator of neurotrophin recptors with memory-enhancing effects and improved mitochondrial function; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research.
|
|
|
April 21, 2022
|
|
A positive modulator of neurotrophin receptors improves cognition and mitochondrial function; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022.
|
|
|
March 17, 2022
|
|
NeuroRestore – Preliminary results from a Single Ascending Dose study in healthy volunteers of ACD856, a positive modulator of Neurotrophin Trk-receptors; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022
|
|
|
March 15, 2022
|
|
CSO Johan Sandin explains the science behind AlzeCure’s project portfolio and what distinguishes it from other pharma companies (Swedish).
|
|
|
March 14, 2022
|
|
Watch the Analysisguide’s interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the future (in Swedish).
|
|
|
March 14, 2022
|
|
CEO Martin Jönsson is interview by BioStock on the company’s latest developments, including the ongoing rights issue.
|
|
|
March 14, 2022
|
|
See CEO Martin Jönsson and CSO Johan Sandin, present upcoming events in the company and the ongoing issue (Swedish).
|
|
|
March 11, 2022
|
|
Watch the interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the ongoing issue (Swedish).
|
|
|
March 9, 2022
|
|
AlzeCure – New presentation at Penser (Swedish).
|
|
|
February 24, 2022
|
|
Latest newsflow (Swedish).
|
|
|
February 3. 2022
|
|
CEO Martin Jönsson presents at Aktiespararna (Swedish).
|
|
|
January 31, 2022
|
|
Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease (Text only).
|
|
|
January 27, 2022
|
|
Alzstatin – Development of novel γ-secretase modulators for the treatment of Alzheimer’s disease.
|
|
|
January 27, 2022
|
|
Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease, Scientific presentation at 11th Pharmaceutical Profiling meeting, January 27, 2022.
|
|
|
January 27, 2022
|
|
AlzeCure Pharma – Kapitalmarknadsdag.
|
|
|
January 18, 2022
|
|
AlzeCure medverkar på Erik Penser Banks temadag Life Science december 2, 2021 (Swedish)
|
|
|
December 2, 2021
|
|
Follow us – Stay updated
|
|
|
November 22, 2021
|
|
AlzeCure Pharma – Redeye Life Science Day
|
|
|
November 11, 2021
|
|
AlzeCure update on the latest developments – Interview with CEO Martin Jönsson about the company, its projects developments in Alzheimer’s and pain, and future plans.
|
|
|
October 22, 2021
|
|
Alzecure presents at Healthcare Innovation Summit
|
|
|
October 7, 2021
|
|
Alzecure Pharma – Naventus Life Science Summit
|
|
|
September 29, 2021
|
|
Aktiespararna interview CEO Martin Jönsson – latest quarterly report and future prospects. (Swedish)
|
|
|
September 20, 2021
|
|
AlzeCure Pharma – Aktiedagen Stockholm. (Swedish)
|
|
|
September 7, 2021
|
|
Development plan for NeuroRestore ACD856 by Dr Johan Sandin, PhD Chief Scientific Officer
|
|
|
September 1, 2021
|
|
NeuroRestore Background and evolution by Dr Pontus Forsell, PhD Head of Discovery & Research
|
|
|
September 1, 2021
|
|
Company Overview & Vision by Martin Jönsson CEO
|
|
|
September 1, 2021
|
|
Alzheimer’s disease and the neurotrophins BDNF/NGF by Prof. Maria Eriksdotter M.D., PhD
|
|
|
September 1, 2021
|
|
Strategy Update on Alzheimer’s Disease & NeuroRestore
|
|
|
September 1, 2021
|
|
ACD856 – a novel positive allosteric modulator of Trk-receptors in clinical development for the treatment of Alzheimer’s disease; Scientific presentation at AAIC, July 26-30, 2021
|
|
|
July 29, 2021
|
|
About suffering from Alzheimer’s disease, diagnostics, care today and future needs – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)
|
|
|
June 11, 2021
|
|
Negative Allosteric Modulators of TrkA for the Treatment of Pain – Scientific presentation at the IASP conference on pain, June 2021
|
|
|
June 11, 2021
|
|
About AlzeCure’s origin and development – An embryo that can be something big – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)
|
|
|
June 11, 2021
|
|
About Alzstatin and drugs for Alzheimer’s disease – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish)
|
|
|
June 11, 2021
|
|
ACD440 – A Novel TRPV1 Antagonist for the Topical Treatment in Neuropathic Pain – Scientific presentation at the IASP conference on pain, June 2021
|
|
|
June 9, 2021
|
|
Alzecure: CEO Martin Jönsson present at Redeye Growth Day
|
|
|
June 7, 2021
|
|
CEO presentation at the annual meeting (Swedish)
|
|
|
May 20, 2021
|
|
CEO Martin Jönsson after the company’s annual meeting
|
|
|
May 17, 2021
|
|
Update on Progress in the Painless Platform, May 11, 2021
|
|
|
May 11, 2021
|
|
Company overview and goals by CEO Martin Jönsson, May 11, 2021
|
|
|
May 11, 2021
|
|
ACD 440 – A novel VR1 antagonist for neuropathic pain by CSO Johan Sandin, May 11, 2021
|
|
|
May 11, 2021
|
|
Chronic Pain – a high unmet medical need by CMO Märta Segerdahl, May 11, 2021
|
|
|
May 11, 2021
|
|
TrkA- NAM – Project in osteoarthritis & other severe pain conditions by Head of Discovery & Research Pontus Forsell, May 11, 2021
|
|
|
May 11, 2021
|
|
Alzecure: Interview with CEO Martin Jönsson and CSO Johan Sandin (video)
|
|
|
April 20, 2021
|
|
Alzecure: Interview with CEOMartin Jönsson (video). (Swedish)
|
|
|
March 1, 2021
|
|
Interview with Martin Jönsson CEO in Aktiespararna’s analysis guide
|
|
|
February 8, 2021
|
|
CEO Martin Jönsson presentation, Aktiedagen Lund
|
|
|
January 27, 2021
|
|
Interview with Johan Sandin (CSO) in Aktiespararna’s analysis guide
|
|
|
January 22, 2021
|
|
Improving Quality of Life for People with Neurodegenerative Diseases – Stockholm Researchers and Health Tech Companies
|
|
|
January 14, 2021
|
|
Alzecure: CEO Martin Jönsson presents at Redeye Life Science Day 2020
|
|
|
December 1, 2020
|
|
Scientific and market update with professor Henrik Zetterberg on Alzheimer’s disease, bio-markers, potential future treatments, including Alzstatin and AlzeCure
|
|
|
September 30, 2020
|
|
AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish)
|
|
|
September 8, 2020
|
|
AlzeCure Science & Market update about Alzheimer’s diseas and NeuroRestore (Swedish)
|
|
|
September 1, 2020
|
|
Get to know AlzeCure’s CEO Martin Jönsson – Redeye interview (Swedish)
|
|
|
March 19, 2020
|
|
AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish)
|
|
|
March 16, 2020
|
|
About Alzheimers disease
|
|
|
February 27, 2018
|
|
About the project NeuroRestore®, symptomatic treatment of cognitive disorders such as in Alzheimer’s disease
|
|
|
February 27, 2018
|
|
Welcome to AlzeCure … Introduction film about the company (Swedish) – 1 minute
|
|
|
|
|
Scientific presentation about ACD856, a positive modulator of neurotrophin signaling reverses scopolamine- or age-induced cognitive deficits
|
|
|
April 2-5, 2020
|
|
Scientific presentation on Alzstatin presented at the CTAD conference
|
|
|
November 4-7, 2020
|
|
Scientific presentation on the NeuroRestore® candidate ACD856 presented at the CTAD conference
|
|
|
November 4-7, 2020
|
|
About the Alzstatin® project Disease modifying treatment of Alzheimer’s disease
|
|
|
|
|
Characterization of positive allosteric modulators of TrkB for the treatment of depression
|
|
|
October 2-5, 2021
|
|
Gamma-secretase modulation results in multiple anti-amyloidogenic effects in vivo; Scientific presentation at the AAT-AD/PD conference, Italy, March 15-18, 2018
|
|
|
March 15-18, 2018
|
